Citizens has reaffirmed its stock rating for Halozyme Therapeutics following the company's robust performance in the first quarter. The financial results showcased significant growth and exceeded market expectations, prompting the firm to maintain its positive outlook on the stock. Analysts at Citizens highlighted key metrics that contributed to this decision, reflecting confidence in Halozyme's ongoing business strategy and market position.
Related Articles
Don't miss out on breaking stories and in-depth articles.